It wasn’t long ago since the genome was fully decoded. Now, Israel’s C2i Genomics (see here previously) has teamed up with Tel Aviv’s Sourasky (Ichilov) Medical Center take blood test data and perform whole genome minimal residual disease (MRD) testing … Continue reading →

CB Insights has named nine Israeli-based health-tech startups in its 2021 Top 150 Digital Health Companies transforming healthcare. They include Vocalis, Sweetch, DiA Imaging, B.Well, C2I Genomics, Lumen, Nym Health, Theator and Empathy. https://www.israel21c.org/8-israeli-startups-make-cb-insights-top-150-list/ https://b-well.co.il/  (Hebrew)

Asaf Zviran co-founded Israel’s C2i Genomics (see here previously). It has developed a blood test that can identify whether a cancer patient will survive after the tumor has been completely removed, or whether further chemotherapy is necessary. https://www.israel21c.org/a-blood-test-that-can-identify-recurrent-cancer/

The PlayBeyondBio initiative has selected nine Israeli startups for its program for companies developing solutions for future challenges to healthcare systems. C2i Genomics, Nucleai, Itamar medical, Medial Earlysign, iBex, Octopus.health, Imagene, iCardio.ai and Cordio Medical. https://www.calcalistech.com/ctech/articles/0,7340,L-3912456,00.html

At its Israeli R&D center, C2i Genomics has developed a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. It employs a breakthrough tumor DNA pattern recognition approach for liquid biopsy. https://en.globes.co.il/en/article-cancer-recurrence-monitoring-co-c2i-genomics-raises-12m-1001331769 https://c2i-genomics.com/